Clostridium difficile in a HIV-infected cohort: Incidence, risk factors, and clinical outcomes

AIDS

Volumn 27, Issue 17, 2013, Pages 2799-2807

  Haines, Charles F ^a   Moore, Richard D ^a   Bartlett, John G ^a   Sears, Cynthia L ^a   Cosgrove, Sara E ^a   Carroll, Karen ^a   Gebo, Kelly A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Case control; Clostridium difficile; HIV; Incidence; Risk factors

Indexed keywords

AMINOPENICILLIN; AZITHROMYCIN; CALCINEURIN INHIBITOR; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; CLOSTRIDIUM TOXIN; COTRIMOXAZOLE; CYTOTOXIN; ERYTHROMYCIN; GATIFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; MACROLIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; MOXIFLOXACIN; MYCOPHENOLIC ACID; NORFLOXACIN; PROTON PUMP INHIBITOR; STEROID;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84888296081     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000432450.37863.e9     Document Type: Review

References (43)

1. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23:529-549.
2. Tumbarello M, Tacconelli E, Leone F, Cauda R, Ortona L. Clostridium difficile-associated diarrhoea in patients with human immunodeficiency virus infection: A case-control study. Eur J Gastroenterol Hepatol 1995; 7:259-263.
3. Willingham FF, Ticona Chavez E, Taylor DN, Bowen AB, Crane AR, Gottlieb AL, et al. Diarrhea and Clostridium difficile infection in Latin American patients with AIDS. Working Group on AIDS in Peru. Clin Infect Dis 1998; 27: 487-493.
4. Kelly CP, Kyne L. The host immune response to Clostridium difficile. J Med Microbiol 2011; 60:1070-1079.
5. Alonso CD, Treadway SB, Hanna DB, Huff CA, Neofytos D, Carroll KC, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54:1053-1063.
6. Barbut F, Meynard JL, Guiguet M, Avesani V, Bochet MV, Meyohas MC, et al. Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:176-181.
7. Sivapalasingam S, Blaser MJ. Bacterial diarrhea in HIV-infected patients: why Clostridium difficile, and why now Clin Infect Dis 2005; 41:1628-1630.
8. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:409-415.
9. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14:929-931.
10. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic SyndrHum Retrovirol 1998; 17 (Suppl 1): S38-S41.
11. Reller ME, Lema CA, Perl TM, Cai M, Ross TL, Speck KA, et al. Yield of stool culture with isolate toxin testing versus a twostep algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol 2007; 45:3601-3605.
12. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
13. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. National Kidney Foundation, Inc; 2002.
14. StataCorp. Stata Statistical Software: Release
15. College Station, TX: StataCorp LP; 2011.
16. Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. Am J Epidemiol 1982; 116:547-553.
17. Sanchez TH, Brooks JT, Sullivan PS, Juhasz M, Mintz E, Dworkin MS, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis 2005; 41:1621-1627.
18. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7:526-536.
19. Shanholtzer CJ, Willard KE, Holter JJ, Olson MM, Gerding DN, Peterson LR. Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests. J Clin Microbiol 1992; 30:1837-1840.
20. Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P, et al. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol 2010; 48:3719-3724.
21. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-2441.
22. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008; 29:823-828.
23. Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett JG. Clostridium difficile colitis: An efficient clinical approach to diagnosis. Ann Intern Med 1995; 123:835-840.
24. Pulvirenti JJ, Mehra T, Hafiz I, DeMarais P, Marsh D, Kocka F, et al. Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients. Diagn Microbiol Infect Dis 2002; 44:325-330.
25. Hutin Y, Molina JM, Casin I, Daix V, Sednaoui P, Welker Y, et al. Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients. AIDS 1993; 7:1441-1447.
26. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390-397.
27. De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, Narita M, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004; 103:2180-2186.
28. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4R lymphocytes. AIDS 1994; 8:469-476.
29. Kroon FP, van Dissel JT, Labadie J, van Loon AM, van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4R T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:1197-1203.
30. Kroon FP, van Dissel JT, Rijkers GT, Labadie J, van Furth R. Antibody response to Haemophilus influenzae type b vaccine in relation to the number of CD4R T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1997; 25:600-606.
31. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000; 19:886-894.
32. Miiro G, Kayhty H, Watera C, Tolmie H, Whitworth JA, Gilks CF, et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005; 192:1801-1805.
33. Collini PJ, Bauer M, Kuijper E, Dockrell DH. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J Infect 2012; 64:131-147.
34. Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc 2012; 87:1046-1053.
35. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pumpinhibitor therapy: A meta-analysis. Am J Gastroenterol 2012; 107:1001-1010.
36. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: the panel on clinical practices for treatment of HIV. Ann Intern Med 2002; 137:381-433.
37. Centers for Disease Control and Prevention. Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012; 61:157-162.
38. Hooshyar D, Hanson DL, Wolfe M, Selik RM, Buskin SE, McNaghten AD. Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS 2007; 21:2093-2100.
39. Tacconelli E, Tumbarello M, de Gaetano Donati K, Leone F, Mazzella P, Cauda R. Clostridium difficile-associated diarrhea in human immunodeficiency virus infection: A changing scenario. Clin Infect Dis 1999; 28:936-937.
40. Health MDoC. Adult and adolescent spectrum of disease project in Michigan Summary Report 1990-2003.
41. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-431.
42. Kaltsas A, Simon M, Unruh LH, Son C, Wroblewski D, Musser KA, et al. Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test results. J Clin Microbiol 2012; 50:1303-1307.
43. Saddi Vr, Glatt Ae. Clostridium difficile-associated diarrhea in patients with HIV: A 4-year survey. J Acquir Immune Defic Syndr 2002; 31:542-543.